INVO Fertility has restructured its leadership to accelerate a clinic-led growth strategy, appointing Terah Krigsvold as chief financial officer and transitioning former CFO Andrea Goren to chief business officer and chief executive of INVO Centers LLC, the company’s wholly owned clinic platform. The move consolidates M&A, new clinic launches, and legal/investor functions under a dedicated commercial operator while maintaining continuity in finance and accounting. INVO currently operates two INVO Centers in the United States and one IVF clinic, and continues to sell its INVOCELL device to third-party fertility practices.
The strategic signal is clear: INVO is doubling down on vertical integration to turn a proprietary device into a differentiated care model. By emphasizing the intravaginal culture procedure enabled by INVOCELL—positioned as a more intimate and potentially lower-cost alternative to conventional IVF—the company is shifting from device distribution to services-led scaling. The central question is whether a clinic roll-up anchored by a unique modality can win on outcomes, cost, and experience fast enough to secure payer and employer adoption in a market where coverage is expanding but scrutiny on value is rising.
This matters now because US fertility demand is climbing, state-mandated coverage is broadening, and employer-sponsored fertility benefits have become a mainstream benefit design lever. Patients could gain access to a more affordable ART option, particularly in geographies where self-pay remains the norm and cost is a primary barrier. Payers and benefits managers, facing rising utilization and high per-cycle costs, will look for credible alternatives that can sustain pregnancy and live birth outcomes with fewer costly add-ons. For reproductive endocrinologists and clinic operators, the adoption calculus hinges on training, workflow integration, and the extent to which IVC can deliver consistent outcomes across patient segments while preserving patient experience advantages.
Commercially, the reallocation of leadership roles points to a more aggressive pipeline of clinic acquisitions and greenfield builds, using clinics both as profit engines and as distribution channels for the INVOCELL-enabled model. This mirrors broader health services trends where medtech and biotech companies pursue services platforms to capture data, control the patient journey, and reduce dependence on third-party adoption. In a capital-constrained environment, services cash flow and asset-backed growth can be a pragmatic alternative to pure-play technology bets. The competitive backdrop is intensifying as integrated fertility networks and benefits platforms seek scale advantages, negotiate national contracts, and standardize protocols; differentiation will likely hinge on demonstrable clinical equivalence or superiority, cost per live birth, and patient-reported outcomes.
For Medical Affairs, the mandate is evidence. Real-world studies comparing IVC with standard IVF across live birth rates, time to pregnancy, discontinuation, and safety will be pivotal, as will health economic models targeted to employers and payers. Clear patient selection criteria and clinician education will influence guideline alignment and quality metrics. For Market Access, engagement with fertility benefits administrators and state policymakers could determine whether IVC earns parity in coverage and coding, or remains primarily a self-pay offering, limiting scale.
The next phase will test whether a clinic-first strategy can catalyze payer confidence and employer uptake around a lower-cost ART pathway. If INVO can substantiate IVC’s clinical and economic profile and embed it within scaled, consistent clinic operations, it could shift the cost curve—and the competitive dynamics—of fertility care. The watch item for 2026: does services-led growth convert into measurable improvements in cost per live birth and coverage penetration, or does the market default back to conventional IVF where networks already control the demand funnel?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
